Trials / Recruiting
RecruitingNCT06672536
Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD
A Multicenter, Dose-escalation and Dose-expansion, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy Characteristics of SCT520FF in Patients With Neovascular Age-related Macular Degeneration
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 82 (estimated)
- Sponsor
- Sinocelltech Ltd. · Industry
- Sex
- All
- Age
- 45 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Multicenter, open-label, multi-dose study to evaluate the safety and tolerability in patients with nAMD treated with SCT520FF.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SCT520FF | SCT520FF dose level 1，IVI |
| DRUG | SCT520FF | SCT520FF dose level 2，IVI |
| DRUG | SCT520FF | SCT520FF dose level 3，IVI |
| DRUG | EYLEA 2 MG | EYLEA 2 MG,IVI,injection once every 4 weeks,during the study period |
Timeline
- Start date
- 2024-11-26
- Primary completion
- 2026-09-23
- Completion
- 2027-01-11
- First posted
- 2024-11-04
- Last updated
- 2025-09-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06672536. Inclusion in this directory is not an endorsement.